echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Slowly growing antihypertensive drug market under the background of centralized procurement

    Slowly growing antihypertensive drug market under the background of centralized procurement

    • Last Update: 2019-12-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Diabetes, cardiovascular diseases and respiratory diseases are also called three "chronic killers" The state attaches great importance to the prevention and treatment of hypertension In the context of drug collection, the price of antihypertensive drugs has dropped significantly In the future, the growth rate of market scale of antihypertensive drugs in China will be relatively slow, the performance of compound antihypertensive drugs will be better, and the drug structure will continue to be reasonable The prevalence of hypertension in China is closely related to work and life habits and diet structure Since the reform and opening up, China's economy has been developing rapidly, the pressure of work and life of residents has been increasing, the intake of high calorie diet has been increasing, the number of hypertension patients has been increasing year by year, and the trend of youth has begun The state attaches great importance to the prevention and treatment of hypertension In October 2019, the medical insurance bureau, the Ministry of finance, the health commission and the Drug Administration jointly issued the guidance on improving the outpatient medication guarantee mechanism for urban and rural residents with hypertension and diabetes mellitus The outpatient medication within the scope of the national basic medical insurance medication catalogue was included in the medical insurance payment, and the reimbursement ratio was increased to more than 50%, greatly reducing the burden of medication for patients According to the guidelines for rational use of hypertension issued by the national health and Health Commission in 2015, the prevalence of hypertension among adults in China has increased from 5.11% in 1959 to 27.9% in 2015 It is estimated that the number of hypertension patients among adults in China will exceed 400 million by 2030 It is reported that more than 80% of patients with cardiovascular diseases suffer from hypertension In China, the number of premature deaths caused by the rise of blood pressure is as high as 2 million every year, and the annual direct medical cost is 36.6 billion yuan Figure 1 the total number and prevalence of hypertension patients in China the overall scale of China's antihypertensive drug market forecasts that in 2018, 7 of the 25 varieties purchased in the "4 + 7" belt will have antihypertensive drugs, among which the price of irbesartan tablets after centralized purchase will drop by 60% With the rapid promotion of generic consistency evaluation and the spread of volume procurement across the country, the price of generic drugs may continue to decline, while the current market share of 78% of the original research drugs will be forced to reduce prices significantly Although the number of hypertension patients in China is increasing, the overall market growth of antihypertensive drugs will be stable and slow under the background of the continuous decline of drug prices According to the sales data of antihypertensive drugs in sample hospitals, the market scale of antihypertensive drugs in China was about 62.1 billion yuan in 2018, up 3.6% year on year According to the weighted calculation of market structure and year-on-year growth rate of antihypertensive drugs in recent three years, the growth rate of market scale of antihypertensive drugs in China is about 2.44% in 2020-2030, and the market scale is expected to reach 85.2 billion yuan by 2030 There are six kinds of antihypertensive drugs in China: calcium antagonists, renin-angiotension-aldosterone system inhibitors, adrenergic receptor blockers, compound antihypertensive drugs, diuretics and sympathetic inhibitors Among them, calcium antagonists, renin-angiotension-aldosterone system inhibitors, adrenergic receptor blockers and compound antihypertensive drugs accounted for 90% of the total market of antihypertensive drugs in 2018 Figure 2 proportion of market scale of various antihypertensive drugs in 2018 1 The change trend of market structure of antihypertensive drugs in China from 2020 to 2030 According to the prediction of change trend of drug structure of antihypertensive drugs, the overall trend of market structure of antihypertensive drugs in China from 2020 to 2030 is shown in the following figure: Figure 3 market scale of antihypertensive drugs in China from 2018 to 2030 Figure 4 market share of various antihypertensive drugs in China from 2018 to 2030 2 Calcium antagonists: the market scale is the highest proportion of calcium antagonists (CCB) has been applied in the clinic for many years Its excellent antihypertensive effect, extensive combined antihypertensive potential and superior cardiovascular and cerebrovascular protection make it play an important role in the current antihypertensive treatment and reduce the incidence rate and mortality of cardiovascular and cerebrovascular diseases In 2018, the market scale of CCB was about RMB 18.76 billion, with a year-on-year growth of 2.8% The market scale accounted for the highest proportion in the whole antihypertensive drug market, with a growth rate slightly higher than the overall growth rate of antihypertensive drugs It is expected that the market scale of CCB will reach RMB 22.14 billion in 2030 In 2018, amlodipine accounted for 31.8% of the market share, with a market scale of 5.96 billion yuan, followed by nifedipine accounting for 25.9%, with a market scale of 4.86 billion yuan It is estimated that the market scale of amlodipine and nifedipine will reach 7.04 billion yuan and 5.73 billion yuan respectively in 2030 Figure 5 distribution of CCB drug market in 2018 3 RAAS inhibitors: the second is slow growth renin-angiotension-aldosterone system (RAAS) inhibitors, which mainly include three types of drugs: ACEI, ARB and renin inhibitors ARB is a new type of antihypertensive drug, which is mainly used in the clinical treatment of antihypertensive and other cardiorenal diseases ACEI has good target organ protection and cardiovascular end-point event prevention effect for hypertensive patients The market scale of RAAS inhibitors in 2018 is about 16.61 billion yuan, up 1.7% year-on-year The market scale of RAAS inhibitors is the second largest in the whole antihypertensive drug market, and the growth rate is lower than the overall growth rate of antihypertensive drugs It is estimated that the market scale of RAAS inhibitors will reach 17.2 billion yuan in 2030 In 2018, the three drugs with the highest market share of RAAS inhibitors are valsartan (22.8%, 3.79 billion yuan), losartan (16.7%, 2.77 billion yuan), and irbesartan (16.6%, 2.76 billion yuan) It is estimated that the market models of valsartan, losartan and irbesartan will be 3.92 billion yuan, 2.87 billion yuan and 2.85 billion yuan respectively in 2030 Figure 6 market size distribution of RAAS inhibitors in 2018 4 Adrenergic receptor blockers: wide indications and rapid growth Adrenergic receptor blockers include β receptor blockers and α receptor blockers β receptor blockers have been used in the treatment of hypertension since 1960s They are recommended as the first choice of antihypertensive drugs by many national hypertension guidelines and widely used in the treatment of hypertension Alpha blockers have been used in clinical practice for many years At present, the main clinical blockers are terazosin, prazosin, doxazosin and urapidil Adrenergic receptor blockers are widely used in the treatment of coronary heart disease, angina pectoris, prostate hypertrophy and other diseases The market scale of adrenergic receptor blockers in 2018 is about 10.61 billion yuan, up 8.4% year-on-year, with a rapid growth rate It is expected that the market scale of adrenergic receptor blockers will reach 17.63 billion yuan in 2030, surpassing RAAS inhibitors to become the third largest class of antihypertensive drugs In 2018, the three drugs with the highest market share of adrenergic receptor blockers were metoprolol (35.3%, 3.75 billion yuan), bisoprolol (22.7%, 2.41 billion yuan), and urapidil (17.4%, 1.85 billion yuan) It is estimated that the market scale of metoprolol, bisoprolol and urapidil in 2030 will be 6.22 billion yuan, 4 billion yuan and 3.06 billion yuan respectively Figure 7 proportion of market scale of adrenergic receptor blockers in 2018 5 Compound antihypertensive drugs: good treatment effect, rapid growth for many hypertensive patients, especially the elderly with hypertension for many years, single drug has been unable to make blood pressure meet the standard, and the combination treatment of more than two drugs has become the preferred scheme The research shows that fixed dose of FDC can bring great benefits to hypertension treatment, and the standard rate of FDC is significantly higher than that of free combination, which can achieve 24-hour stable hypotension and have better compliance The market scale of compound antihypertensive drugs in 2018 is about 10.36 billion yuan, with a year-on-year growth of 4.1% The growth rate is relatively fast It is expected that the market scale of compound antihypertensive drugs will reach 21.09 billion yuan in 2030 and become the second largest class of antihypertensive drugs In 2018, the three drugs with the highest market share in the compound antihypertensive drugs were valsartan amlodipine (35.1%, 3.64 billion yuan), irbesartan hydrochlorothiazide (18.3%, 1.89 billion yuan), and losartan potassium hydrochlorothiazide (13.6%, 1.41 billion yuan) It is estimated that the market scale of the three drugs in 2030 will be 74% respectively Billion yuan, 3.86 billion yuan and 2.87 billion yuan Figure 8 conclusion of market size distribution of compound antihypertensive drugs in 2018 The market scale of antihypertensive drugs has been growing slowly in recent two years, and there are few new products on the market In the future, with more domestic imitated antihypertensive drugs passing the consistency evaluation, centralized collection and capacity expansion, the price of antihypertensive drugs will continue to decline, and the market scale of antihypertensive drugs will maintain a slow growth trend, while the market share of adrenergic receptor blockers with wider indications and compound antihypertensive drugs with better therapeutic effects will gradually increase Increase.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.